



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |                      |
|---|----------------------|
| Applicant(s): Jackson, et al.                       |                      |
| Application No.: 10/828,395                         | Group Art Unit: 1614 |
| Filed: 4/19/2004                                    | Examiner:            |
| Title: Method for Treatment of Angiogenic Disorders |                      |
| Attorney Docket No.: UBC.P-032                      |                      |

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the above-captioned application. Copies of the listed non-U.S. references are enclosed.

No fees are believed due for this IDS since we have not received an action on the merits. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

Respectfully Submitted,

Marina T. Larson, Ph.D  
Attorney/Agent for Applicant(s)  
Reg. No. 32038


(970) 468 6600

Cert. USPTO 1.8  
This paper and the attachments contained herein are being deposited with the United States Postal Service with sufficient postage for first class mail and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on

MAR - 4 2005

Name Lianna McCarthy

Signature Lianna McCarthy



(Use as many sheets as necessary)

Sheet

1

of

6

Application Number

10/828.395

Filing Date

4/19/2004

First Named Inventor

Jackson et al.

Art Unit

1614

Examiner Name

UBC.P-032

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>9</sup> |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>2</sup> -Number <sup>3</sup> - Kind Code <sup>4</sup> (if known) |                                |  |   |                |
|                    |                       | WO 00/34469  | 06-15-2000                     | The Research Foundation of                         |   |                |
|                    |                       | WO 00/49937  | 08-31-2000                     | The University of British                          |   |                |
|                    |                       | WO 01/46455 A2   | 06-28-2001                     | Yale University                                    |   |                |
|                    |                       | WO 02/22635 A1   | 03-21-2002                     | ISIS Pharmaceuticals, Inc.                         |   |                |
|                    |                       | WO 03/062421 A1  | 07-31-2003                     | The University of British                          |   |                |
|                    |                       | WO 03/072591 A1  | 09-04-2003                     | The University of British                          |   |                |
|                    |                       | WO 2004/018675 A1  | 03-04-2004                     | The University of British                          |   |                |
|                    |                       | WO 2004/018676 A2  | 03-04-2004                     | The University of British                          |   |                |
|                    |                       |  |                                |  |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |   |    |                          |                        |           |
|---|---|----|--------------------------|------------------------|-----------|
| <b>Substitute for form 1449B/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |           |
|   |   |    | Application Number       | 10/828,395             |           |
|   |   |    | Filing Date              | 4/19/2004              |           |
|   |   |    | First Named Inventor     | Jackson et al.         |           |
|   |   |    | Art Unit                 | 1614                   |           |
| Sheet   | 2 | of | 6                        | Examiner Name          |           |
|   |   |    |                          | Attorney Docket Number | UBC.P-032 |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 |                          | AGRAWAL ET AL., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(s) 72-81, Volume 6, Publisher: Elsevier Science Ltd.  |                |
|                                 |                          | AOKI ET AL., RNA Interference may be more potent than antisense RNA in human cancer cell lines, Clinical and Experimental Pharmacology and Physiology, 2003, Page(s) 96-102   |                |
|                                 |                          | BENNER ET AL., Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies, Journal of Pharmacological and Toxicological Methods, 1997, Page(s) 229-235, Publisher: Elsevier Science Inc.                                  |                |
|                                 |                          | BORAL ET AL., Clinical evaluation of biologically targeted drugs: obstacles and opportunities, Cancer Chemother Pharmacol, 1998, Page(s) S3-S21, Publisher: Springer-Verlag   |                |
|                                 |                          | ANDREA D. BRANCH, A good antisense molecule is hard to find, TIBS, 1998, Page(s) 45-50, Publisher: Elsevier Science Ltd.  |                |
|                                 |                          | STEVEN BREM, MD, Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Cancer Control Journal, 1999, Volume 6, Number 5, Publisher: H. Lee Moffitt Cancer Center & Research Institute   |                |
|                                 |                          | BRUCHOVSKY ET AL., Control of Tumor Progression by Maintenance of Apoptosis, www.prostatepointers.org, 1996, Publisher: Wiley-Liss, Inc.  |                |
|                                 |                          | BUTTYAN ET AL., Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death, Molecular and Cellular Biology, 1989, Page(s) 3473-3481, Volume 9, Number 8, Publisher: American Society for Microbiology  |                |
|                                 |                          | COX ET AL., Angiogenesis and non-small cell lung cancer, Lung Cancer, 2000, Page(s) 81-100, Publisher: Elsevier   |                |
|                                 |                          | CROOKE ET AL., Basic principles of antisense therapeutics, Antisense Research and Application, 2004, Page(s) 1-50, Chapter 1, Publisher: Springer   |                |
|                                 |                          | DARBY ET AL., Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity, Exp Nephrol, 1995, Page(s) 234-239, Publisher: S. Karger AG   |                |


|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |   |    |   |                          |                |
|---|---|----|---|--------------------------|----------------|
| <b>Substitute for form 1449B/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                |
|   |   |    |   | Application Number       | 10/828,395     |
|   |   |    |   | Filing Date              | 4/19/2004      |
|   |   |    |   | First Named Inventor     | Jackson et al. |
|   |   |    |   | Art Unit                 | 1614           |
| Sheet   | 3 | of | 6 | Examiner Name            |                |
|   |   |    |   | Attorney Docket Number   | UBC.P-032      |

| NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---------------------------------|--------------------------|---|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                             | T <sup>2</sup> |
|                                 |                          | DIEMER ET AL., Expression of Porcine Complement Cytolysis Inhibitor mRNA in Cultured Aortic Smooth Muscle Cells, The Journal of Biological Chemistry, March 15, 1992, Page(s) 5257-5264, Volume 207, Number 8, Publisher: The American Society for Biochemistry and Molecular Biology, Inc. |                |
|                                 |                          | GENTA, New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment, www.genta.com, 2001  |                |
|                                 |                          | GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2,, Urology, , Page(s) 39-49, Volume 58  |                |
|                                 |                          | GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, , Page(s) 79-92, Volume 21   |                |
|                                 |                          | GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen-, Investigational New Drugs, , Page(s) 145-158, Volume 20, Number 2, Publisher: XP 009021411  |                |
|                                 |                          | GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced prostate Cancer, Current Drug Targets, , Page(s) 209-221, Volume 4  |                |
|                                 |                          | JEN ET AL., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 307-319, Volume 18   |                |
|                                 |                          | JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, , Page(s) 427-431, Volume 34, Publisher: XP002262319   |                |
|                                 |                          | KADOMATSU ET AL., Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate., Cancer Res April 1 1993 Page(s) 1460-1465 Volume 53 Number 7  |                |
|                                 |                          | KIRBY ET AL. Bartonella-associated endothelial proliferation depends on inhibition of apoptosis, PNAS, April 2, 2002, Page(s) 4656-4661, Volume 99, Number 7  |                |
|                                 |                          | KYPRIANOU ET AL., bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate , International Journal of Cancer, January 27, 1997, Page(s) 341-348, Volume 70, Number 3  |                |

|                       |                    |
|-----------------------|--------------------|
| Examiner<br>Signature | Date<br>Considered |
|-----------------------|--------------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |   |    |   |                          |                |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449B/PTO   |   |    |   | <b>Complete if Known</b> |                |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/828,395     |
|   |   |    |   | Filing Date              | 4/19/2004      |
|   |   |    |   | First Named Inventor     | Jackson et al. |
|   |   |    |   | Art Unit                 | 1614           |
|   |   |    |   | Examiner Name            |                |
| Sheet   | 4 | of | 6 | Attorney Docket Number   | UBC.P-032      |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 |                       | LEE ET AL., In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator, The Prostate Supplement, 2000, Page(s) 21-24, Volume 9, Publisher: Wiley-Liss, Inc.  |                |
|                                 |                       | MILLAR ET AL., Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous, International Journal of Andrology, 1994, Page(s) 149-160, Volume 17  |                |
|                                 |                       | MILLIS ET AL., Clusterin Regulates Vascular Smooth Muscle Cell Nodule Formation and Migration, Journal of Cellular Physiology, 2001, Page(s) 210-219, Volume 186, Publisher: Wiley-Liss, Inc.   |                |
|                                 |                       | MILNER ET AL., Selecting effective antisense reagents on combinatorial oligonucleotide arrays, Nature Biotechnology, 1997, Page(s) 537-541, Volume 15   |                |
|                                 |                       | MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both..., Clinical Cancer Research, 5/1/2000, Page(s) 1655-1663, Volume 6   |                |
|                                 |                       | MIYAKE ET AL., Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in..., Cancer Research, 1/1/2000, Page(s) 170-176, Volume 60   |                |
|                                 |                       | MIYAKE ET AL., Synergistic Chemosensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide..., Clinical Cancer Research, , Page(s) 4245-4252, Volume 7   |                |
|                                 |                       | MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic ..., International Journal of Urology, , Page(s) 337-349, Volume 8, Number 7, Publisher: XP002262321                       |                |
|                                 |                       | NOR ET AL., Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice, Laboratory Investigation, 2001, Page(s) 453-463, Volume 81, Number 4   |                |
|                                 |                       | NOR ET AL., Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth, March 1, 2001, Page(s) 2183-2188, Volume 61  |                |
|                                 |                       | OPALINSKA ET AL., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews. 2002, Page(s) 503-514, Volume 1  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |   |    |   |                          |                |
|---|---|----|---|--------------------------|----------------|
| Substitute for form 1449B/PTO   |   |    |   | <b>Complete if Known</b> |                |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | Application Number       | 10/828,395     |
|   |   |    |   | Filing Date              | 4/19/2004      |
|   |   |    |   | First Named Inventor     | Jackson et al. |
|   |   |    |   | Art Unit                 | 1614           |
|   |   |    |   | Examiner Name            |                |
| Sheet   | 5 | of | 6 | Attorney Docket Number   | UBC.P-032      |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                        | T <sup>2</sup> |
|                                 |                       | ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., , Page(s) 633-645, Volume 27, Number 7, Publisher: XP001002844  |                |
|                                 |                       | SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor $\alpha$ in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 , Cancer Research, , Page(s) 2431-2437, Volume 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082 |                |
|                                 |                       | TRAN ET AL., A role for survivin in chemoresistance of endothelial cells mediated by VEGF, PNAS, April 2, 2002, Page(s) 4349-4354, Volume 99, Number 7   |                |
|                                 |                       | TROUGAKOS ET AL., Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces , Cancer Research, March 1, 2004, Page(s) 1834-1842, Volume 64   |                |
|                                 |                       | VICKERS ET AL., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, The Journal of Biological Chemistry, February 28, 2003, Page(s) 7103-7118, Volume 278, Number 9  |                |
|                                 |                       | WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biological Sciences, 3/1/2000, Page(s) 95-98, Volume 25, Number 3, Publisher: Elsevier Science, Ltd., XP004202536  |                |
|                                 |                       | WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neuro..., European Journal of Biochemistry, , Page(s) 917-925, Volume 227, Number 3, Publisher: XP 001146404   |                |
|                                 |                       | WRIGHT ET AL., A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate , Experimental Cell Research, January 10, 1996, Page(s) 54-60, Volume 222, Number 1  |                |
|                                 |                       | YANG ET AL., Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death, PNAS, May 23, 2000, Page(s) 5507-5512, Volume 97, Number 11  |                |
|                                 |                       | ZANGEMEISTER-WITTE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both hcl-2 and hcl-xl Expression Efficiently Induces ....., Clinical Cancer Research, 6/1/2000, Page(s) 2547-2555, Volume 6   |                |
|                                 |                       | ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of ....., The Journal of Pharmacology and Experimental, 5/11/2001, Page(s) 934-940, Volume 298, Number 3  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

|       |   |    |   |
|-------|---|----|---|
| Sheet | 6 | of | 6 |
|-------|---|----|---|

**Complete if Known**

|                    |            |
|--------------------|------------|
| Application Number | 10/828.395 |
|--------------------|------------|

|                    |           |
|--------------------|-----------|
| <i>Filing Date</i> | 4/19/2004 |
|--------------------|-----------|

|                      |                |
|----------------------|----------------|
| First Named Inventor | Jackson et al. |
|----------------------|----------------|

|          |      |
|----------|------|
| Art Unit | 1614 |
|----------|------|

*Examiner Name*

|                        |           |
|------------------------|-----------|
| Attorney Docket Number | UBC.P-032 |
|------------------------|-----------|

NON PATENT LITERATURE DOCUMENTSExaminer  
Initials\*

Cite  
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $T^2$ 

ZELLWEGER ET AL., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting..., Neoplasia, , Page(s) 360-367, Volume 3, Number 4

ZWAIN ET AL., Clusterin Protects Granulosa Cells from Apoptotic Cell Death during Follicular Atresia, *Experimental Cell Research*, 2000, Page(s) 101-110, Volume 257, Publisher: Academic Press

Examiner  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.